EMPOWERED PATIENT PODCAST: Developing Immunotherapies Using Oncolytic Viruses to Change the Tumor Microenvironment Written by Paul Peter Tak on November 18, 2021. Posted in Projects. Leave a Comment https://empoweredpatientradio.com/developing-immunotherapies-using-oncolytic-viruses-to-change-the-tumor-microenvironment-with-dr-paul-peter-tak-candel-therapeutics
Pillars of success for building an innovative organisation. Written by Paul Peter Tak on October 27, 2021. Posted in Projects. Leave a Comment
The Netherlands: ‘Boston by the North Sea?’ Written by Paul Peter Tak on October 8, 2021. Posted in Projects. Leave a Comment
Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer Written by Paul Peter Tak on September 11, 2021. Posted in Projects. Leave a Comment https://www.biospace.com/article/releases/candel-therapeutics-completes-enrollment-in-phase-3-clinical-trial-of-can-2409-in-combination-with-valacyclovir-for-the-treatment-of-intermediate-high-risk-localized-prostate-cancer/
A glorious moment, knowing that we have secured the proceeds to deliver on our mission to develop better medicines for patients Written by Paul Peter Tak on September 11, 2021. Posted in Projects. Leave a Comment
My message to the Candel Therapeutics team and stakeholders (patients, collaborators, and investors) in 90 sec Written by Paul Peter Tak on September 5, 2021. Posted in Projects. Leave a Comment
Paul Peter Tak named to PharmaVoice’s 100 List Written by Paul Peter Tak on August 5, 2021. Posted in News. Leave a Comment https://www.pharmavoice.com/digital-edition/july-august-2021/#62
We’re excited to join the @Nasdaq family! Now #NasdaqListed and trading: $CADL. Learn more about our IPO here: https://bit.ly/3i5UcnL Written by Paul Peter Tak on July 29, 2021. Posted in Projects. Leave a Comment
I’m happy to announce that Candel Therapeutics appoints Diem Nguyen, Ph.D., M.B.A., to Its Board of Directors Written by Paul Peter Tak on July 24, 2021. Posted in Projects. Leave a Comment https://www.businesswire.com/news/home/20210715005303/en/Candel-Therapeutics-Appoints-Diem-Nguyen-Ph.D.-M.B.A.-to-Its-Board-of-Directors
Exciting times at Candel Therapeutics: Written by Paul Peter Tak on June 28, 2021. Posted in Projects. Leave a Comment Erasing cancer, reviving oncolytic virus, treating a rare neuromuscular condition: Here’s what you need to know about the 5 new biotechs filing for IPOs
